title: Treatment of neuroblastoma with [125I]metaiodobenzylguanidine.
abstract: To find a treatment that may be effective against micrometastases of advanced, stage III or IV neuroblastoma, [125I]metaiodobenzylguanidine (125I-MIBG) was used in a phase I toxicity trial. In seven patients, thrombocytopenia was encountered with absorbed whole body doses of 85-135 rad from 125I-MIBG, but the dosimetry was imprecise in predicting bone marrow injury. Three patients survived for over one year, results that may indicate efficacy of 125I-MIBG therapy.
authors.affiliation: Department of Internal Medicine, University of Michigan, Ann Arbor 48109-0028.
authors.forename: J C
authors.initials: JC
authors.lastname: Sisson
authors.forename: B
authors.initials: B
authors.lastname: Shapiro
authors.forename: R J
authors.initials: RJ
authors.lastname: Hutchinson
authors.forename: K R
authors.initials: KR
authors.lastname: Zasadny
authors.forename: S
authors.initials: S
authors.lastname: Mallette
authors.forename: E E
authors.initials: EE
authors.lastname: Mudgett
authors.forename: D M
authors.initials: DM
authors.lastname: Wieland
mesh_terms: D019797:3-Iodobenzylguanidine; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D006801:Humans; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*; D007462:Iodobenzenes / Q000009:adverse effects / Q000627:therapeutic use*; D009447:Neuroblastoma / Q000628:therapy*; D013921:Thrombocytopenia / Q000209:etiology
chemical_list: D000970:Antineoplastic Agents; D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D019797:3-Iodobenzylguanidine